Vertex Pharmaceuticals is making significant strides in addressing critical kidney diseases, with key advancements in treatments for IgAN, AMKD, and ADPKD. These developments are crucial as they pave the way for innovative therapies that aim to tackle the root causes of these conditions, ultimately improving patient outcomes.
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). These updates represent significant progress toward reaching the Company’s goal of bringing forward first-in-class or best-in-class therapies that target the underlying cause of these serious kidney diseases. Povetacicept
Source: Original Press Release
